Skip to main content
Premium Trial:

Request an Annual Quote

Tripos to Acquire Pharsight for $57M

NEW YORK (GenomeWeb News) – Bioinformatics firm Tripos today said that it will acquire drug development software and regulatory services firm Pharsight for approximately $57 million in cash.
Tripos, which is owned by private equity firm Vector Capital, will pay $5.50 for each outstanding share of common stock of publicly traded Pharsight. The price represents a 29 percent premium over the average closing price of Pharsight’s stock for the 30-day trading period ended Sept. 8. Pharsight’s shares closed at $3.99 on the Nasdaq yesterday.
Pharsight Chairman and CEO Shawn O’Connor said the merger would enable the firm to expand its offerings and market reach. “The combined companies will provide software products and scientific services over an expanded market, from discovery to Phase III, approval, and post marketing,” O’Connor said in a statement.
Pharsight’s board of directors has approved the transaction, which must also be approved by the Mountain View, Calif.-based firm’s shareholders. The firms expect to close the deal in the fourth quarter of 2008.

Filed under

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.